Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the Behavioural Situation by Clément, Yan et al.
Pharmacological Alterations of Anxious Behaviour in
Mice Depending on Both Strain and the Behavioural
Situation
Yan Cle ´ment
1,3*, Anne-Marie Le Guisquet
2, Patrice Venault
3, Georges Chapouthier
4, Catherine Belzung
2
1Universite ´ Reims Champagne-Ardenne, Reims, France, 2Psychobiologie des e ´motions, Universite ´ Franc ¸ois Rabelais de Tours, Faculte ´ des Sciences et Techniques, Parc
Grandmont, Tours, France, 3Universite ´ Pierre et Marie Curie-Paris 6, CNRS, UMR 7225, Inserm, U 975, Paris, France, 4USR CNRS 3246 Groupe Hospitalier Pitie ´-Salpe ˆtrie `re,
Paris, France
Abstract
A previous study comparing non-emotive mice from the strain C57BL/6/ByJ with ABP/Le mice showed ABP/Le to be more
anxious in an open-field situation. In the present study, several compounds affecting anxiety were assayed on ABP/Le and
C57BL/6/ByJ mice using three behavioural models of anxiety: the elevated plus-maze, the light-dark discrimination test and
the free exploratory paradigm. The compounds used were the full benzodiazepine receptor agonist, chlordiazepoxide, and
the antagonist, flumazenil, the GABAA antagonist, bicuculline, the full 5-HT1A agonist 8-OH-DPAT, and the mixed 5-HT1A/5-
HT1B agonist, RU 24969. Results showed the effect of the compounds to be dependent on both the strain and the
behavioural task. Several compounds found to be anxiolytic in ABP/Le mice had an anxiogenic effect on C57BL/6/ByJ mice.
More behavioural changes were observed for ABP/Le in the elevated plus-maze, but the clearest findings for C57BL/6/ByJ
mice were observed in the light-dark discrimination apparatus. These data demonstrate that anxious behaviour is a complex
phenomenon which cannot be described by a single behavioural task nor by the action of a single compound.
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Introduction
Anxiety is a widespread phenomenon occurring in response to
various stressors. In humans, there is not one single syndrome, but
several which may explain different anxiety conditions reported
and could provide evidence for hypotheses on the involvement of
certain biological substrates [1,2]. Anxiety in animals is less clear,
given the obvious difficulty in assessing psychological components,
but it has been suggested that anxiety is not a single phenomenon.
Studies of rodents have assessed anxiety using animal models of
fear, e.g. the light/dark test and the elevated plus-maze paradigm
to measure state anxiety, and the free exploratory test to measure
trait anxiety [3–10].
It has been suggested that several factors, environmental and
genetic, can be seen in the aetiology of anxiety, with genetic factors
in both humans and animals regulating the physiological processes
involved in anxiety [11,12]. Studies have shown phenotypic
differences in inbred strains of mice [13–19] and many loci have
been associated with an increase in the behavioural expression of
anxiety [11,20–22]. When the genetic factors involved are located
on eight or more chromosomes, the behaviour patterns are said to
depend on a multigenic system and the genetic background [1,23].
The strain ABP/Le (hereafter ABP) strain was found to be more
anxious than C57BL/6/ByJ (hereafter B6) and the 4
th,7
th and 9
th
murine chromosomes were found to be associated with anxiety
[13,14]. Since two of the three chromosomes (7
th and 9
th
chromosomes) putatively involved in anxiogenic processes contain
loci encoding for either the GABAA receptor subunits (a5, b3, c3)
or for the 5-HT1B receptor, the hypothesis of a biochemical
correlate with anxiogenic behaviour patterns was tested. Binding
studies were conducted and the anxious phenotype was found to
be present with modifications caused by the BZ antagonist
[
3H]flumazenil and the 5-HT1B receptor agonist [I
125]cyanolo-
pindolol [24,25].
Many previous studies have found clear evidence of the
anxiolytic effects of GABAA-BZ receptor ligands [26–28].
Benzodiazepine (BZ) agonists have anxiolytic properties, whereas
BZ inverse agonists have an anxiogenic effect. Studies of in vivo
administration of serotoninergic (5-HT) ligands have failed to find
clear evidence of either an anxiolytic or an anxiogenic effect when
administered to animals, including effects dependent on the
behavioural model, the dose or the 5-HT receptor subtype.
Full 5-HT1A agonists have, however, often been seen to produce
anxiolytic effects in animals, yet in humans partial agonists are
used to relieve anxiety [29–32]. Activation of the 5-HT1B receptor
can also increase anxiety [33,34]. A number of pharmacological
studies have been confirmed by experimental studies using
knockout animals. Decreased GABAA-receptor clustering, and
inactivation of the gene coding for the 5-HT1A receptor have been
seen to induce anxiety-like behaviour [35–39]. Observations of 5-
HT1B receptor knockout mice, however, did not find any
consistent modification in anxiety levels [40,41].
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GABAA-BZ and 5-HT neurotransmission systems may be
involved in an animal model of anxiety, and that genetic factors
may determine differential sensitivity to specific drugs. In line with
previous studies [4,10,42], the behavioural analysis was conducted
after in vivo administration of one of a number of compounds: the
full BZ agonist, chlordiazepoxide (5 mg/kg), the BZ antagonist,
flumazenil (3 mg/kg), the GABAA antagonist, bicuculline (1 mg/
kg), the 5-HT1A agonist 8-OH-DPAT (0.3 mg/kg) and the mixed
5-HT1A/5-HT1B agonist, RU 24969 (2.5 mg/kg). Three animal
models of anxiety were used: the elevated plus-maze, the light-dark
test procedure and the free exploratory paradigm. The study was
designed as a pilot study to analyse two different transmitter
systems (GABA-BZ and 5-HT). For ethical reasons to minimise
the number of animals used, only one dose of each compound was
administered. The compounds were selected for their relevance as
reported in the literature.
Materials and Methods
Animals
The animals were male and female mice bred in the laboratory
from two parent strains: ABP/Le (n=151) and C57BL/6ByJ
(n=185). They were reared under standard conditions: temper-
ature 23.560.5uC. A 12:12 h photoperiod with lights on at 8:00
am, tap water and Souriffarat (IM UAR) feed available ad libitum,
and dust-free softwood sawdust bedding. Litters were culled to 7
subjects at birth. From birth to weaning, the animals were kept
with their mothers only; the sires were removed from the mating
cages one or two days before parturition. Male and female
offspring were separated when weaned at 30+2 days. The animals
were 10 weeks old 6 2 weeks when tested. All experiments
complied with the ethical guidelines laid down by the French
Ministry of Agriculture and with the European Council Directive
86/609/EEC.
Behavioural testing
The experiments were conducted in a room outside the
breeding room between 13.00 h and 17.00 h. Data were recorded
using a hand-held computer (Psion Organiser). An independent
group of mice was used for each behavioural test. The tables give
details of the number of animals in each. Mice were naive to the
test apparatus.
Light-dark apparatus
Two polyvinyl chloride boxes (20620614 cm) covered with
Plexiglas were connected via a semi-opaque plastic tunnel
(567610 cm). One box was dark, while the other box was lit by
a 100 W desk lamp 20 cm above the box; this was the only light in
the room. The subjects were individually tested in 5-min sessions.
The mouse was placed in the lit box to start the test session. The
parameters recorded were the time spent in the lit box, the
number of transitions (i.e. the mouse crossing and placing all four
paws in the opposite box) and the number of entries into the
tunnel after the first entry (an entry being defined as more than 2
seconds spent in the tunnel).
Elevated plus-maze
The apparatus was a polyvinyl chloride plus-maze with two lit
open arms (2765 cm) and two closed arms (2765615 cm)
covered with cardboard to block out the light; all four arms
radiated from a central platform (565 cm). The apparatus was
mounted on a base raising the arms to a height of 38.5 cm above
the floor. To initiate the test session, the mouse was placed on the
central platform, facing an open arm, and was observed for 5 min.
The mouse was considered to be on the central platform whenever
two paws were on it, and in one of the arms when all four paws
were inside. The following behavioural variables were recorded,
counting both number and duration: entries into an open arm,
entry into a closed arm and unprotected head-dipping (the animal
extending its head into the open, below the open arm).
Free exploratory paradigm (Hughes Box)
The apparatus consisted of a polyvinyl chloride box
(30620620 cm) covered with Plexiglas and subdivided into six
identical square exploration units, all interconnected by small
doors. A temporary partition divided the apparatus in half
lengthwise. Approximately 24 h before testing, each subject was
placed in one half of the apparatus, with the temporary partition in
place, to be familiarised with it. The floor was covered with
sawdust and the animal was given unlimited access to food and
water. The next day, the same mouse was exposed to both the
familiar and novel environments after the temporary partition was
removed, but without the animal being removed from the box.
The subject was then observed under red light for 10 min.
Parameters recorded were the number of episodes of avoidance
behaviour in response to the novel environment (attempts), the
number of units entered (locomotion), the number of rearings and
the time spent in the novel side.
Drugs
Chlordiazepoxide HCl (Sigma, L’Isle D’Abeau, France) (5 mg/
kg), suspended in a vehicle, was administered 30 min before
testing. RU 24969 (Tocris, Illkirch, France) (2.5 mg/kg), dissolved
in a vehicle, was administered 40 minutes before testing. 8-OH-
DPAT (Sigma, L’Isle D’Abeau, France) (0.3 mg/kg) and fluma-
zenil (donated by Hoffmann-La Roche, Basle, Switzerland) (3 mg/
kg) were dissolved in saline and injected 20 minutes before testing.
Bicuculline (Sigma, St. Louis, MO) (1 mg/kg) was dissolved in hot
saline and mixed with acetic acid to produce a final concentration
of approximately 0.01 M; this was done because bicuculline is
unstable in physiological pH. The cooled solution was injected 10
minutes before testing. All the drugs were administered by
intraperitoneal injection; the volume injected was 10 ml/kg body
weight. The vehicle injection was saline with one drop of Tween
80 and one drop of acetic acid, and was injected 20 minutes before
testing (i.e. the approximate harmonic mean of the intervals before
behavioural testing). Each animal was given one injection, either
an active drug or saline solution.
Statistical analysis
A multivariate analysis of variance was performed with
‘‘Strain’’, ‘‘Treatment’’ and ‘‘Gender’’ as the main components,
plus their interactions using a GLM SAS procedure followed by
planned contrast comparisons. Partial comparisons were done
using the adjusted means with the Least Squares Means
(LSMeans) statement of GLM (SAS). Strain * Treatment
interaction was also tested.
Results
Light-dark apparatus (Table 1)
A Strain effect was observed, but only for the number of entries
into the tunnel, F1,98=8.09, p=0.005; it also showed a Treatment
effect which was significant for time spent in the lit box and the
number of transitions, F5,98=3.29, p=0.009; F=4.45, p=0.001,
respectively.
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number of transitions, F5,98=4.51, p=0.0001. Neither the Strain
* Treatment * Gender interaction, nor the Strain * Gender or
Treatment * Gender interactions were significant. As no Gender
effect was observed, male and female data were pooled for the
partial comparisons.
Partial comparisons after:
- Saline solution and 8-OH-DPAT treatment: no treatment or
strain effect was observed.
- Chlordiazepoxide (CDZ)
The number of transitions and the number of entries into the
tunnel were lower for ABP than for B6, t=6.97, p=0.017,
t=10.51, p=0.005, respectively.
CDZ increased the number of entries into the tunnel for B6 but
not for ABP, t=1.97, p=0.05.
- Bicuculline
There was no difference in behaviour between ABP and B6.
Bicuculline treatment when compared to saline did, however,
reduce the time spent in the lit box and the number of transitions
by B6 but not by ABP: t=3.03, p=0.003; t=2.94, p=0.006,
respectively. The treatment (bicuculline vs saline) reduced the
number of entries into the tunnel by both strains: t=3.63,
p=0.007; t=2.80,p=0.006, respectively.
- Flumazenil
No strain effect on behaviour was observed between ABP and
B6, but a treatment effect (flumazenil vs saline) was observed, with
both B6 and ABP spending less time in the lit box: t=1.92,
p=0.05; t=1.76, p=0.08, respectively.
- RU 24969
The number of transitions and the number of entries into the
tunnel were higher for ABP than for B6: t=2.96, p=0.009;
t=5.60, p=0.0003, respectively.
Compared to saline treatment, RU 24969 treatment caused a
decrease in time spent in the lit box but only by B6, not by ABP,
while the number of transitions and the number of entries into the
tunnel increased in ABP, but not in B6: t=2.30, p=0.02; t=3.66,
p=0.004, respectively.
Elevated plus-maze (Table 2)
A Strain effect was observed for the time spent in the open arms:
F 1.79=71.98, p=0.0001.
The Treatment factor was significant for the duration head-
dipping, F=3.27, p=0.010. A Strain * Treatment interaction was
observed for head-dipping, F=2.66, p=0.028, respectively.
Partial comparisons after:
- Saline treatment
The number of entries into the open arms and the number of
head-dippings were higher in ABP than in B6: t=2.39, p 0.019;
t=1.98, p=0.050 respectively.
- 8-OH-DPAT
The number of entries into the open arms was higher in ABP
strain than in B6, t=2.47, p=0.016.
The treatment caused a decrease in head-dippings and entries
in the closed arms in ABP but not in B6: t=1.75, p=0.08;
t=2.00, p=0.05, respectively.
- Chlordiazepoxide
The ABP mice spent longer and recorded more entries into the
open arms as well as more head-dippings than B6: t=3.57,
p=0.0006; t=3.31, p=0.002; t=2.43, p=0.017, respectively.
CDZ caused an increase in the time spent in the open arms by
ABP, but not by B6: t=1.95, p=0.05.
- Bicuculline
The duration and number of entries into the open arms and the
duration and number of head dippings were higher in ABP than in
B6: t=3.67, p=0.0005; t=4.80, p=0.0001; t=3.59, p=0.0006,
t=3.01, p=0.004, respectively.
Bicuculline caused an increase in the time spent in the open
arms by ABP but not by B6, t=2.84, p=0.006.
- Flumazenil
The time spent in the open arms, and the number and duration
of head-dippings were higher in ABP than in B6: t=3.89,
p=0.0002; t=4.15, p=0.0001; t=2.10, p=0.039, respectively.
Flumazenil caused an increase in the time spent in the open
arms by ABP but not by B6: t=2.05, p=0.043.
- RU 24969
The time spent and the number of entries into the open arms
were higher in ABP than in B6, t=3.34, p=0.001; t=4.45,
p=0.000, respectively. The number and duration of head-
dippings were also higher in ABP strain than in B6; t=4.59,
p=0.0001; t=2.05, p=0.042, respectively.
RU 24969 caused an increase in the number of entries and
duration in the open arms and the number and duration of head-
Table 1. Comparison (mean6S.E.M.) of ABP and B6 mice + drug treatment (mg/kg) in light-dark apparatus.
Saline solution 8-OH-DPAT 0.3 mg Chlordiazepoxide 5 mg Bicuculline 1 mg
Behaviour ABP n=9 B6 n=8 ABP n=5 B6 n=10 ABP n=7 B6 n=10 ABP n=6 B6 n=9
Time spent in lit box 49.367.0 70.1610.* 47.767.6 46.469.9 57.8612.0 53.1613.7 Q 29.266.8 22.968.9 Q
Number of transitions 6.060.9 7.361.3 5.860.8 5.160.1 5.2.760.7 q 8.160.8 * 4.160.8 2.161.1 Q
Number of entries in tunnel 16.761.6 16.662.2 15.361.8 15.062.4 14.761.6 q 22.661.8 q* 12.561.7 Q 7.062.3 Q
Saline solution Flumazenil 3 mg RU 24969 2.5 mg
Behaviour ABP n=9 B6 n=8 ABP n=8 B6 n=9 ABP n=8 B6 n=9
Time spent in lit box 49.367.0 70.1610.0 * 33.7 6.2 Q 41.267.8 Q 49.868.0 35.3610.5 Q
Number of transitions 6.060.9 7.361.3 4.860.7 4.660.9 10.761.3 q 4.361.7 *
Number of entries in tunnel 16.761.6 16.662.2 15.561.8 12.562.3 30.862.1 q 11.462.7 *
NB: Figures on time spent in tunnel and time spent in dark box not given; data not significant.
*Strain difference (ABP vs. B6).
qincreased behaviour by treatment (drug mg/kg) vs. saline).
Qdecreased behaviour by treatment.
doi:10.1371/journal.pone.0007745.t001
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p=0.005; t=2.81, p=0.006; t=1.86, p=0.067, respectively.
Free Exploratory Paradigm, Hughes Box (table 3)
Three-way ANOVA showed Treatment x Strain interactions
for rearing, F5,123=5.70, p=0.001, and for time spent in the
novel area, F5,123=5.46, p=0.001. A Strain x Gender interac-
tion was found to be significant for rearing, F1,123=4.66,
p=0.03. This appears to be the only Gender interaction with
another factor, and was only small in magnitude; the interaction
was therefore considered fortuitous and the factor was not
included in the analysis. The Treatment factor was significant for
locomotion, rearing and times p e n ti nt h en o v e la r e a :
F5,123=13.53, p=0.001; F=3.56, p=0.005; F=2.93, p=0.01,
respectively. A Strain effect was observed for the same
parameters: F1,123=25.58, p=0.001; F=8.59, p=0.004;
F=14.61, p=0.001, respectively. The Gender effect reached
significance for rearing and t h et i m ei nt h en o v e la r e a :
F1,123=7.26, p=0.008; F=5.84, p=0.01, respectively. The
number of attempts was not different.
Effects of Treatments
- Saline treatment
Novelty preference (time in novel side) was lower in B6 than in
ABP: t=4.28, p=0.001.
- 8-OH-DPAT
Locomotion and rearing were lower for ABP than for B6:
t=3.11, p=0.005; t=3.18, p=0.005, respectively.
No effect of 8-OH-DPAT was seen in either strain.
- Chlordiazepoxide
Rearing decreased in ABP mice compared to B6: t=2.04,
p=0.05.
No treatment effect was detected.
- Bicuculline
The two strains recorded different times spent in the novel side,
with B6 mice displaying a lower novelty preference: t=2.85,
p=0.01.
Bicuculline, compared with controls, caused a decrease in
novelty preference, but only in B6: t=2.08, p=0.05.
- Flumazenil
The two strains had different results: locomotion and rearing
were lower in ABP than in B6: t=2.61, p=0.01; t=3.85,
p=0.001, respectively.
The treatment effect was not significant.
- RU 24969
Between-strain differences were observed for all variables tested:
locomotion was lower, t=2.02, p=0.05; time in the novel side,
attempts and rearing were higher in ABP than in B6, t=5.03,
p=0.001; t=2.02, p=0.05; t=2.73, p=0.01, respectively.
RU 24969 increased locomotion in both ABP and B6: t=4.00,
p,0.001; t=2.98; p=0.007, respectively. Drug treatment de-
creased the time spent in the novel side in B6, but not in ABP:
t=3.84, p=0.001.
Discussion
An animal is usually considered anxious if it spends less time in
the lit box of a light-dark apparatus, does less exploration of the
open arms of a plus-maze apparatus and spends less time in the
novel side of the free exploratory apparatus [4,8,15,36,43]. Using
these three tests, recognised as models of anxiety in rodents,
(tables 1, 2 & 3), and a comparative design with and without
pharmacological treatment, we studied the anxiety behaviour of
two inbred strains, ABP and B6. Saline treated controls showed
strain-dependent differences in behaviour, most significantly in the
plus-maze model and the free exploratory test. In the plus-maze,
ABP mice recorded more entries into the open arms and more
head-dippings (table 2), more rearing and grooming (data not
included). In the free exploratory test, ABP mice spent more time
Table 2. Comparison (mean6S.E.M.) of ABP and B6 mice + drug treatment (mg/kg) in elevated plus-maze.
Saline solution 8-OH-DPAT 0.3 mg Chlordiazepoxide 5 mg Bicuculline 1 mg
Behaviour ABP n=7 B6 n=10 ABP n=5 B6 n=10 ABP n=7 B6 n=10 ABP n=5 B6 n=9
Entries on the open arm Nb. 19.665.2 5.063.5 * 13.665.2 3.762.4 * 25.464.4 6.663.7 * 25.865.2 3.961.7 *
Dn. 41.1617.5 14.061.7 62.7617.4 10.4612.3 85.7614.7 q 16.9612.3 * 111.4617.5 q 6.8613.0 *
Entries on the enclosed arm Nb. 29.664.4 22.362.9 17.264.4 Q 22.563.1 23.963.7 25.563.1 24.664.4 29.363.3
Dn. 111.0629.4 91.5619.8 52.7629.4 88.7620.7 123.8624.8 104.0620.7 70.2629.3 97.96621.9
Head dipping Nb. 23.464.2 7.663.0 * 12.864.2 Q 5.663.0 27.063.6 9.263.0 * 26.064.3 6.863.1 *
Dn. 20.764.6 9.763.1 * 10.864.6 4.863.3 24.363.9 11.963.2 * 24.164.6 6.763.4 *
Saline solution Flumazenil 3 mg RU 24969 2.5 mg
Behaviour ABP n=7 B6 n=10 ABP n=5 B6 n=8 ABP n=6 B6 n=10
Entries on the open arm Nb. 19.665.2 5.063.5 * 32.465.2 2.664.1 42.764.8 q 9.663.7 *
Dn. 41.1617.5 14.061.7 91.9617.4 q 5.3613.8 * 103.2615.9 q 35.6612.3 *
Entries on the enclosed arm Nb. 29.664.4 22.362.9 30.264.4 27.063.5 33.764.0 16.963.1
Dn. 111.0629.4 91.5619.8 69.8629.4 90.6623.2 84.4626.8 86.0620.7
Head dipping Nb. 23.464.2 7.663.0 * 28.264.3 5.663.3 * 39.763.8 q 7.363.0 *
Dn. 20.764.6 9.763.1 * 23.164.6 5.063.6 * 32.364.2 q 7.863.2 *
Nb. =Number; Dn. =Duration (secondes).
*Strain difference (ABP vs B6).
qincreased behaviour by treatment (drug mg/kg vs. saline).
Qdecreased behaviour by treatment.
doi:10.1371/journal.pone.0007745.t002
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behaviour cannot be linked to any difference in the level of
locomotion, as not only were there no strain-related differences for
entries into the closed arms, but in the free exploratory test, the
general activity of B6 mice was higher than ABP mice.
It must be noted that these results do not appear to tally with
previous findings obtained in open-field testing, where ABP mice were
f o u n dt ob em o r ea c t i v et h a nB 6[ 2 5 ] .D i f f e r e n c e si ne x p e r i m e n t a l
situations may account for this discrepancy and clear out a complex
interaction between genetic and environmental factors [44,45].
The pharmacological action of selected compounds was
reported using the same 3 tests and 2 strains, showing, for
example, that the effects on ABP mice in the elevated plus-maze
were always anxiolytic, and that the effects on B6 mice in the
light/dark apparatus were always anxiogenic.
Two comments can be made at this point. First, it could be
argued that the ABP strain may be a better murine model for
studying the anxiolytic effects of drugs, while the B6 strain would be
better suited to uncovering anxiogenic effects. But some compounds
were also seen to have anxiolytic effects on B6 mice [46–49].
Secondly, it could be argued that when experimenting with mice,
the light/dark choice test may be more relevant for detecting
anxiogenic effects, while the plus-maze may be better suited to
measuring anxiolytic effects, even though anxiolytic effects have
been clearly observed using the same version of the light/dark
apparatus ([42,50–52] 52 Griebel et al., 1992), and anxiogenic
actions have been observed in the elevated plus-maze [53–56].
The administration of chlordiazepoxide (benzodiazepine recep-
tor agonist) induced anxiolytic effects in ABP mice tested in the
elevated plus-maze, confirming the anti-anxiety effects of benzo-
diazepine agonists which have been extensively reported. Howev-
er, the same effect was not observed in ABP mice in the light/dark
test, providing further evidence for the argument that the two tests
assess different behaviour patterns. This is not a new discovery;
diazepam has been shown to produce anxiolytic effects in Swiss,
BALB/c and C3HeOuJIco mice in either the elevated plus-maze
test or the light/dark choice test; yet the same compound, at the
same dose, produced anxiolytic effects in C57BL/6JIco, DBA/
2JIco, NMRI and NZB/Ola/Hsd mice in the elevated plus-maze,
but not in the light/dark choice test [47,57].
Flumazenil (benzodiazepine receptor antagonist) is usually
described as devoid of intrinsic action in rodent models of anxiety,
such as conditioned conflict paradigms [58,59], the elevated plus-
maze [60,61], the light/dark choice test [62], the staircase [62,63],
the burying test [64] and ultrasonic vocalisations [65]. Yet
flumazenil has also been described as an anxiogenic agent for
testing in the elevated plus-maze [66,67], the social interaction
model [68,69] and the mouse defence test battery [58,70]; it has
been shown to produce an inverse agonist-like promnesic effect in
a learning task [71]. In some cases it has even been described as
agonistic [72,73]; e.g. rats trained to discriminate clorazepate from
saline extend the cue to include flumazenil [74]. In some
situations, flumazenil has been seen to induce agonist or inverse
agonist-like effects, depending on the level of threat or stress [75–
77], and on the strain used [47]. In the present study, the
benzodiazepine antagonist was anxiolytic in ABP mice in the
elevated plus-maze but had an anxiogenic effect on the B6 mice in
the light/dark apparatus. As pharmacological reactions were
induced in both strains, it is difficult to implicate pharmacokinetic
differences in any explanation of behavioural differences. The
treatment*strain interaction confirms that the effects of flumazenil
depend upon environmental and genetic factors.
The behavioural effects of the GABAA receptor antagonist,
bicuculline, are also strain-dependent. Bicuculline induced anxiety
in B6 mice in both the free exploratory test (a decrease in the time
spent in the novel environment) and the light/dark test, but induced
an anxiolytic effect on ABP mice in the elevated plus-maze. As ABP
and B6 mice were both sensitive to bicuculline, the differences
observed should not be related to pharmacokinetic differences. The
anxiogenic effects of the GABAA receptor antagonist are not
surprising given that benzodiazepines are believed to produce their
anxiolytic effect by increasing GABAergic neurotransmission.
Another experiment obtained similar results using very high doses
(up to 8 mg/kg) [78]. But no consistent evidence of an anxiogenic
profile has been found [79] and it has been suggested that when
anxiogenesis is observed after bicuculline administration, it may be
attributed to behavioural suppression rather than to any effect on
anxiety; for example, a dose of 1 mg/kg produced behavioural
suppression in Swiss mice in the free exploratory test [80]. This was
not found in the present study; in the free exploratory test, bicuculline
Table 3. Comparison (mean6S.E.M.) of ABP and B6 mice + drug treatment (mg/kg)in free exploratory paradigm.
Saline solution 8-OH-DPAT 0.3 mg Chlordiazepoxide 5 mg Bicuculline 1 mg
Behaviour ABP n=13 B6 n=12 ABP n=11 B6 n=10 ABP n=12 B6 n=13 ABP n=10 B6 n=10
Time in novel side (sec.) 481.3611.4 410.5611.96 * 441.2632.5 438.6619.4 374.5654.4 375.0619.4 476.3627.1 307.2652. Q *
Attempts 2.760.6 1.760.9 2.461.0 1.260.5 2.660.7 4.661.5 2.260.8 2.260.7
Locomotion 99.4611.0 132.4614.6 75.4611.9 127.7611.8 * 90.9617.5 131.7612.7 77.865.3 101.8614.8
Rearing 33.265.0 40.265.6 17.463.3 33.263.7 * 17.365.5 31.564.3 * 27.464.5 34.966.1
Saline solution Flumazenil 3 mg RU 24969 2.5 mg
Behaviour ABP n=13 B6 n=12 ABP n=13 B6 n=14 ABP n=14 B6 n=13
Time in novel side (sec.) 481.3611.4 410.5611.9 * 397.4634. 417.5611.2 461.7620.1 290.0628 Q *
Attempts 2.760.6 1.760.9 3.861.1 3.661.5 7.7862.2 2.461.5 *
Locomotion 99.4611.0 132.4614.6 85.6612.8 127.8 610.0 * 162.1611.1 q 207.7620.1 q *
Rearing 33.265.0 40.265.6 19.664.6 44.564.5 * 47.864.6 29.265.1 *
*Strain difference (ABP vs B6).
qincreased behaviour by treatment (drug mg/kg vs saline).
Qdecreased behaviour by treatment.
doi:10.1371/journal.pone.0007745.t003
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effect of the GABAA receptor antagonist on the ABP strain is
surprising and may be related to dysfunction of the GABAA receptor.
In a previous study [25], [
3H]flumazenil binding in brain
homogenates of ABP and B6 micewas measured after exposure to a
novel situation. Scatchard analysis showed greater affinity in the
BZR binding sites of the ABP strain. Kd changes may indicate that
certain animals considered as ‘‘more anxious’’ have fast adaptive
cellularmechanisms,causinganincreaseinBZRaffinityinresponse
to novelty-induced stress.The different behaviour patterns observed
in the present report after administering flumazenil or bicuculline
may be explained by differential qualitative changes in both strains
(i.e. changes in the molecular stoechiometry of the GABAA
receptors) or by a rapid post-transcriptional regulatory mechanism,
such as phosphorylation of the receptor protein. The possibility,
however, that different allelic forms encoding for GABAA receptors
may be correlated with the pharmacological profiles observed
cannot be excluded. The ABP linkage-testing strain is interesting as
it contains a genetic marker (pink-eyed dilution,7
th chromosome) close
to loci encoding for the a5 and b3 GABAA protein receptor [81].
Many mRNAs encoding for these proteins are found in the cortex
(a5 and b3) and in the hippocampus (mainly a5). As these loci co-
segregate in intercrossed F2 Mendelian populations (easily identi-
fiable animals) and since the a5 subunit has been associated with the
pharmacological effects of benzodiazepines [82], further pharma-
cological experiments on these populations (p/p F2), using specific
and high affinity ligands for these receptors, could clarify the
putative role of these GABA and BZ binding sites in anxiety.
Administration of 8-OH-DPAT (full5-HT1A agonist)hadnoeffect
in the light-dark apparatus and there was no strain difference in drug
sensitivity, confirming previous data [24,83]. In the plus-maze and
the free exploratory paradigm we observed some minor effects which
also corroborated the findings of previous studies [4,43,61].
RU 24969, a mixed 5-HT1A/5-HT1B agonist, produced
anxiolytic effects in ABP mice in the elevated plus-maze, while it
produced anxiogenic effects in B6 mice in the elevated plus-maze
and the free exploratory test. A review of the literature shows RU
24969 to have either anxiolytic or anxiogenic effects, depending
on the behavioural test used; it is usually anxiogenic in the elevated
plus-maze test and has been reported as being anxiolytic in a
modified Vogel test and in the four plate test [84]. The interaction
observed in the present study is therefore not surprising and
contributes new data. The administration of RU 24969 stimulated
locomotion in the free exploratory test in both strains, but RU
24969 produced opposite effects on anxiety in the two strains,
suggesting that while the drug affects locomotion, it may not affect
the expression of anxiety. Assuming that the effects of RU 24969
on locomotion can be linked to 5-HT1B within the striatum, it may
be that the two strains differ in their expression of 5-HT1B in other
brain areas, e.g. the limbic system. The 5-HT1B receptors are
mainly found in extrapyramidal neural pathways, and these are
mainly presynaptic terminal autoreceptors which inhibit the
release of 5-HT in the cortex and substantia nigra. The 5-HT1B
receptors are also heteroreceptors and modulate the release of
other neurotransmitters; for example, 5-HT inhibits ACh release
in the hippocampus. In the globus pallidus and the substantia
nigra, GABA release is inhibited by 5-HT1B activation [57,85]. In
a previous study, quantitative autoradiography [I
125] was used to
measure cyanolopindolol binding sites in different areas of the
brain in ABP and B6 mice [24]. An increase was observed in the
density of 5-HT1B in the globus pallidus and substantia nigra of
the more ‘‘anxious’’ and more active ABP mice, confirming the
involvement of striatal 5-HT1B receptors in locomotion. Unfortu-
nately no data are available on binding sites in the limbic system of
the mice. The ABP strain also has a genetic marker which is close
to a locus encoding for the 5-HT1B subtype. The short-ear (se)
locus (9
th chromosome), expresses itself in an easily identifiable
phenotype [86]. It is thus possible to make segregating populations
homozygous for the se gene, and consequently cosegregate for the
5-HT1B gene. This population can be used for measuring
differential mRNA 5-HT1B and/or 5-HT1B protein expression
in areas of the limbic system such as the hippocampus. It may then
be assumed that the 5-HT1B gene could be mutated in the ABP
strain and correlated with a differential pharmacological pattern.
The present data challenge the conventional view that the
anxiolytic effect of benzodiazepines is the same regardless of the
behavioural situation, although this may still be the case for certain
specific strains of mice. When applied to another mouse strain, as
evidenced the present study, several compounds known to be
anxiolytic, displayed a clearly anxiogenic profile. Furthermore, the
anxious phenotype also depends on characteristics of the
behaviour test used. Finally, more data with more than one dose
are indeed necessary before concluding in anxiogenic or anxiolytic
effect of such a ligand, mainly because interaction between Strain
X Environment X Treatment is complex.
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